

Frequency of Vancomycin-Resistant *Enterococci* Isolated from Clinical Samples of Shahid Mohammadi Hospital through the E-Test Method

Zeynab. Ghalandarzadeh Daryaii¹ Sadeigheh. Javadpour² Mohammad. Kargar³

MSc Student of Microbiology¹, Infectious Disease Research Center, Associate Professor Department of Microbiology², Molecular Medicine Research Center, Hormozgan University of Medical Sciences, Banadr Abbas, Iran. Associate Professor Department of Microbiology³, Islamic Azad University, Jahrom Branch, Jahrom, Iran.

(Received 20 July, 2013

Accepted 20 Nov, 2013)

Original Article

Abstract

Introduction: *Enterococci* are gram-positive coccoid bacteria that are present in the normal flora of the gastrointestinal tract in human, and many mammals and birds, as well as the environment. Vancomycin-resistant *Enterococci* (VRE) are a major and rising problem in hospitals throughout the world. The present study aimed to investigate the frequency of strains of *Enterococci* and the pattern of drug sensitivity in clinical samples.

Methods: This cross-sectional study was conducted on 54 samples of *Enterococcus* in 2012. The diagnostic kit of RapID STR System was used for identification of *Enterococcus* species. Antibiotic sensitivity was determined by Kirby-Bauer disk diffusion method according to CLSI instructions. E-Test was used to determine Vancomycin MIC.

Results: Of the 54 isolates of *Enterococci*, the obtained strains included 38 *E. faecalis* (70.40%), 10 *E. faecium* (18.50%), 3 *E. hirae* (5.55%), one *E. mundtii* (1.85%), one *E. durans* (1.85%), and one *E. avium* (1.85%). Thirteen strains had vancomycin MIC>32 µg/mL. They had the highest resistance to gentamicin and cephalexin by 70.40% and the lowest resistance to linezolid by 3.70%. The highest resistant strain was obtained from urine (76.9%) and internal ward (46.1%).

Conclusion: The substantial abundance of VRE isolated from the study area necessitates the performance of controlling measures.

Key words: Vancomycin-Resistant *Enterococcus* - Antibiotic – Hospital.

Citation: Ghalandarzadeh Daryaii Z, Javadpour S, Kargar M. Frequency of Vancomycin-Resistant *Enterococci* Isolated from Clinical Samples of Shahid Mohammadi Hospital through the E-Test Method. Hormozgan Medical Journal 2015; 19(4): 211-217.

Correspondence:
S. Javadpour, PhD.
Molecular Medicine Research
Center Hormozgan University
of Medical Sciences.
Bandar Abbas, Iran
Tel: +98 9123795367
Email:
sadeighejavadpour@yahoo.com

Introduction:

The word *Enterococcus* is originated from the Greek words of enteron meaning intestine and kokkus meaning grain (1). *Enterococci* are fermentative gram-positive cocci which are present in the colon as the normal flora in almost equal number of *E. coli*. They are also distributed in the

environment where they can survive for a long time given their high tolerance to dryness (2-3). *Enterococci* have little potential for disease and lack strong toxins and notable pathogens; however, they can cause diseases such as bacteremia, endocarditis, and infections of surgical wounds, urinary tract, newborns, central nervous system, abdomen, and pelvis (2, 4-6). The main problem of nosocomial

enterococcal infections is the emergence of multi-resistance to antibiotics (2). According to the national nosocomial infections surveillance system (NNIS), *Enterococcus* is the fourth causing agent of hospital infections (the third cause of bacteremia and the second cause of urinary tract infections) (7). About 90% of enterococcal infections in humans are caused by *E. faecalis* and the remaining 10% by *E. faecium* (8). These strains are considered fecal. Other strains are seen with a very low percentage in clinical samples. It has been suggested recently that specific subsets of this species can be considered as environmental rather than fecal, in particular *E. casseliflavus*, *E. gallinarum*, and *E. mundtii* (9).

Vancomycin was produced in 1958 for the treatment of staphylococcal infections, but was not significantly utilized until the late 1970s and outbreak of methicillin-resistant *Staphylococcus aureus* (10). Vancomycin was first used in clinical cases in 1972 (11). Vancomycin-resistant *Enterococci* were first seen in 1986 in Europe and in 1987 in USA, and then throughout the world, with an increasing detection thereafter (12). The mechanisms of resistance of *Enterococci* to antimicrobial agents, *i.e.* intrinsic (low-level resistance to penicillin, cephalosporins, and aminoglycosides) and acquired (resistance to glycopeptides, high concentrations of aminoglycosides), are now of great importance and attention (7). No single factor shows a good activity against even glycopeptides-sensitive members in this genus (13). In clinical patients, treatment with a combination of agents active on the cell wall, such as penicillin or glycopeptide with aminoglycoside or cephalosporins with bactericidal activity, can be effective (13,14). Production of vaccines and immunotherapy are currently raised for the treatment of enterococcal infections (15-17). This study aimed to determine the prevalence of vancomycin-resistant *enterococci* in clinical samples of Shahid Mohammadi Hospital, in Bandar Abbas and to determine the pattern of antibiotic resistance in 2012.

Methods:

This descriptive study was performed on 54 patients admitted to Shahid Mohammadi Hospital of Bandar Abbas City for one year. There was no limit on age, gender, and cause of admission to be enrolled in this study. All samples were transferred to the laboratory of Microbiology, Faculty of Medicine of Bandar Abbas. They were then incubated on nutrient

agar medium (Merck) for 24 hours at 37°C. The grown bacteria were examined with gram stain and catalase test, and were confirmed through the tests of Bile Aesculin agar (Merck), TSB containing 6.5% salt (Merck), and growth at 45°C. The genus of *Enterococcus* was identified with RapID STR System kit (Remel Company). The panel of this kit includes 10 wells and 14 tests. The tests are based on substrate analysis and reaction of the resulting products with indicators. Hemolysis should also be reported in addition to 14 tests performing for this kit. As a result, a total of 15 tests were evaluated. Since the diagnostic kit of RapID STR System cannot differentiate *Streptococcus durans*, *E. hirae*, *E. casseliflavus*, and *E. mundtii*, these strains were identified through the motion and growth test at 45°C (18). The resistance phenotype was determined through the disc diffusion method according to CLSI guidelines using the following discs; vancomycin 30 mg, ampicillin 10 mg, linezolid 30 mg, imipenem 10 mg, ticoplanin 30mg (Mast Company), and trimethoprim (1.25) + sulfamethoxazole (23.75), ceftizoxime 30 mg, gentamicin 10 mg, and cephalixin 30mg (Himedia Company). Opacity of 0.5 McFarland was used to inoculate into Mueller Hinton agar (Mast). In this study, MIC was determined through E-Test or MIC Test Strip. After placing the E-Test on Mueller Hinton plate, the plates were incubated at 37°C for 18 hours. The lowest concentration of antibiotic in the presence of which no growth was occurred was defined as MIC, and according to the Company's guidelines, the minimum inhibitory concentrations greater than 32 µg/mL, 6-12 µg/mL, and less than 4 µg/mL were interpreted as resistant, intermediate, and sensitive, respectively. Strains of *E. faecalis* ATCC 29212 and *E. faecium* BM4147 were used as negative and positive controls, respectively. MIC was determined for all samples. Statistical analysis was performed with SPSS-19 using chi-square test and Fisher's exact test when necessary, and p -value<0.05 was considered statistically significant.

Results:

Within a year, 54 different strains of *Enterococci* were obtained from clinical samples of patients who were 53.7% male and 46.3% female, with an age range of 9 months to 96 years, an average age of 52.27±3.119 years, and median of 57 years. The mean

length of stay was 8 days with a maximum of 59 days and a minimum of 1 day.

Table 1- Type and number of clinical samples collected (%)

Clinical sample	Urine	Wound	Peritoneal fluid	Blood	Trachea
Frequency	42 (77.80%)	8 (14.80%)	2 (3.70%)	1 (1.85)	1 (1.85%)

The majority of samples were obtained from urine (42) and the least from blood and peritoneal fluid (1) (Table 1).

The results of strain identification using kits and supplementary tests are shown in Table 2.

Table 2- The identified *Enterococcus* species

<i>Enterococcus</i> species	Number	Frequency
<i>E. faecalis</i>	38	70.40%
<i>E. faecium</i>	10	18.50%
<i>E. hirae</i>	3	5.55%
<i>E. durans</i>	1	1.85%
<i>E. avium</i>	1	1.85%
<i>E. mundtii</i>	1	1.85%

Regarding the pattern of antibiotic resistance, the highest resistance was against gentamicin and

cephalexin and the lowest against linezolid (Table 3).

Table 3- Enterococci antimicrobial resistance pattern

Antibiotic	Resistant	Semi-sensitive	Sensitive
Linezolid	3.70%	0	96.30%
Ampicillin	18.50%	0	81.50%
Ticoplanin	20.40%	0	79.60%
Imipenem	20.40%	0	79.60%
Vancomycin	24.10%	0	75.90%
Ceftizoxime	57.40%	3.70%	38.90%
Cotrimoxazole	63%	0	37%
Cephalexin	70.40%	0	29.60%
Gentamicin	70.40%	0	29.60%

Based on the pattern of resistance to antibiotics, the prevalence of multi-drug resistance (MDR) was obtained, and the highest strains (33.33%) were resistant to three drugs (Fig. 1).




Figure 1- Frequency of multi-drug resistant strains of *Enterococcus*

No significant relationship between strains of *Enterococci* and vancomycin resistance was found based on Chi-square statistical analysis (pvalue=0.08).

Strains of vancomycin-resistant *Enterococcus* included *E. faecalis* with 6 strains (46.15%), *E. faecium* with 4 strains (30.78%), *E. avium* with one

strain (7.69%), *E. durans* with one strain (7.69%), and *E. hirae* with one strain (7.69%).

Regarding vancomycin-resistant strains in hospital wards, 6 strains (46.15%) were from the internal ward, 5 strains from the outpatient department (38.47%), one strain (7.69%) from the burning ward, and one strain (7.69%) from the intensive care unit.

The most frequent resistant strains were from the urine samples with a frequency of 10 (76.93%).

Strains with high-level resistance to vancomycin have grown throughout the plate. Among the resistant strains, the minimum inhibitory concentration (MIC) was 48 in one strain, 64 in one strain, more than 256 in the remaining resistant strains which were grown throughout the plates (Table 4).

Table 4- Measurements of MIC by Vancomycin E-test

MIC (mg/mL)	MIC <4 µg/mL	MIC 8-12 µg/mL	MIC >32 µg/mL
Frequency	41	0	13

Conclusion:

Studies performed in Iran have shown that *Enterococci* are the first cause of urinary tract infection among gram-positive cocci and the third cause of urinary tract infection in women in Iran after *Escherichia coli* and *Klebsiella pneumoniae* (19).

In our research, as expected, the most isolated strains were *E. faecalis* (70.4%) followed by *E. faecium* (18.5%). In most studies also, *E. faecalis* and *E. faecium* have been reported as the first and second causes, and the other strains were more or less similar to this study.

In a study by Fatholahzadeh *et al.* in 2006, the identified strains were *E. faecalis* (38%), *E. faecium* (25%), *E. mundtii* (25%), and *E. raffinosus* (12%) (20).

Although we are faced with a relative difference in the incidence, there exist similar strains in hospitals, except for *E. raffinosus* which was not found in the samples. However, regarding its small percentage, if sample collection duration and sample size increased, perhaps we would find this strain as well. In a study by Schouten *et al.* in Europe, the prevalence of *Enterococcus* strains was reported as follows (21): *E. faecalis* (83%), *E. faecium* (13.6%), *E. gallinarum* (1.20%), *E. durans* (0.71%), *E. casseliflavus* (0.53%), *E. avium* (0.46%), *E. hirae* (0.12%), *E. mundtii* (0.05%), and *E. raffinosus* (0.02%) (22). Schouten *et al.* conducted a study in 27 countries of Europe and found a greater variety of strains; this can be attributed to the extensive study performed in various European countries with large size sample

(21). Perhaps if the number of samples and hospitals was reduced, the variety of the viruses would be decreased. Among 180 clinical samples, Mohammadi *et al.* found 128 strains of *E. faecalis* (71.1%) and 52 strains of *E. faecium* (28.9%) (23). In a study by Nouhi *et al.*, out of 76 samples, 59.2%, 38.1%, and 2.7% were *E. faecalis*, *E. faecium*, and *E. gallinarum*, respectively (23). Strains of *Enterococcus* from clinical samples in a study by Guiney and Uriwin included 84.4% *E. faecalis*, 14.8% *E. faecium*, and 0.8% other species including *E. casseliflavus*, *E. avium*, and *E. durans* (24).

Unlike the results of the present study and a majority of research performed in Iran and abroad, Oskoe and Farrukh reported 17 strains of *E. faecium* and 15 strains of *E. faecalis* out 32 of strains (25). In their study, the number of strains of *E. faecium* and *E. faecalis* had a slight difference, and as mentioned earlier, the number of *E. faecalis* could be increased if the sample size increased.

The size of samples obtained from hospital wards varies in different studies, but urine samples usually formed the majority of clinical samples (18-23). In the present study, the rate of VRE was about 24%; while 34% of samples in the study of Ghafarpassand *et al.* (2007) performed on clinical samples of Shahid Beheshti Hospital were resistant to vancomycin (7). Unlike the present study, Salah *et al.* carried out their research on renal patients and strains of *E. faecalis* in 2008 through the disc diffusion method and found that 100% of strains were susceptible to vancomycin (26). In the study Fatholahzadeh *et al.* in 2006, about 7% of the isolates were resistant to vancomycin (20). Harris *et al.* reported a VRE prevalence of 10% (27).

Increased frequency of vancomycin resistant *Enterococci* isolated from clinical samples is consistent with increasing use of antibiotics to which *Enterococci* are naturally resistant. In particular, consumption of cephalosporins and quinolones which are largely effective against gram-negative bacteria has significantly increased. These antibiotics may pave the way to the advent of *Enterococcus* as hospital-acquired pathogen. It is difficult to proof this hypothesis, but circumstantial evidence is compelling. For example, many controlled studies have shown that nosocomial enterococcal infections are related to treatment with beta-lactams antibiotic (imipenem) and quinolone (25).

In this study, the greatest resistance was observed against cephalixin and gentamicin, and linezolid and imipenem were the best treatment options. In a study by Ghasemi *et al.* in Shahid Beheshti Hospital and Shabihkhani Maternity Hospital in 2008 carried out on strains of *E. faecalis* isolated from clinical samples, resistance to gentamicin, ampicillin, imipenem, and vancomycin was reported as 38.7%, 11.3%, 10.4%, and 4.7%, respectively. Multi-drug resistant phenotype was observed in 37.7% of strains (28). In this study, gentamicin and cephalixin had the highest rate of resistance, but vancomycin had not the least resistance. In most studies, same as the present research, linezolid was the least resistant (linezolid resistance pattern was not reported by Ghasemi *et al.*). In the study of Ghafarpassand *et al.* in 2007 on clinical samples in Shahid Beheshti Hospital, 60%, 44%, 34%, and 33% of the strains were resistant to ampicillin, gentamicin, vancomycin, and linezolid, respectively (7). Resistance to ampicillin, vancomycin, and linezolid in the study of Ghafarpassand *et al.* was higher than the present research which can be due to difference in the consumption of drugs in hospitals, the resistance rate of the organism in the hospital, and hospital environments. In this study, the rate of vancomycin-resistant *enterococci* was high, and requires controlling and preventive measures.

Acknowledgment:

The author would like to express his gratitude to the Deputy of Research and Technology of Bandar Abbas Faculty of Medical Sciences for financial support and supplying resources.

References:

1. Patel R. Clinical impact of vancomycin-resistant enterococci. *J. Antimicrob. Chemother* 2003; 51(3):13-21.
2. Huycke MM, Sahm DF, Gilmore MS. Multi-Drug-Resistant Enterococci: The nature of the problem and an agenda for the future. *Emerg Infect Dis* 1998; 4(2):239-49.
3. Nowroozi J, Kargar J. Bacterial Pathogenesis Molecular Approach Salyers A, Whitt D. Tehran: Jufari Press; 2008: 82-98. [In Persian]
4. Cetinkaya Y, Fallk P, Mayhall C. Vancomycin-Resistant Enterococci. *Clin Microbiol Rev* 2000; 13(4):686-707.
5. Murray BE. The life and times of the enterococcus. *Clin Microbiol Rev* 1990; 3(1):46-65.
6. Dougherty S. Role of enterococcus in intraabdominal sepsis. *Am J Surg* 1984; 148(3):308-12.
7. Ghaffarpassand I, Moniri R, Kheradi E. The Prevalence of fecal carriage of antibiotic resistant enterococci among hospitalized patients in Shahid Beheshti hospital, Kashan, Iran at 2007. *Feyz Journal of Kashan University of Medical Sciences. FEYZ Journal* 2010; 14(1):70-5. [In Persian]
8. Gordon S, Swenson J, Hill B, Pigott N, Facklam R. Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. *J Clin Microbiol* 1992; 30(9):2373-8.
9. Maraccini PA, Ferguson DM, Boehm AB. Diurnal variation in Enterococcus Species composition in polluted ocean water and a potential Role for the Enterococcal Carotenoid in Protection against Photoinactivation. *Appl Environ Microbiol* 2012; 78(2):305-10.
10. Afkhamzadeh A, Askarian M, Barari M, Hadinia B, Jokar M. Comparison of the rate of enteric colonization with vancomycin-resistant enterococci in medical wards with surgical wards of Namazi Hospital in Siraz. *Kurdistan University of Medical Sciences Journal* 2008; 13(3):7-14. [In Persian]
11. Fisher K, Phillips C. The ecology, epidemiology and virulence of Enterococcus. *Microbiology* 2009; 155(6):1749-57.
12. Portillo A, Ruiz-Larrea F, Zarazaga M, Alonso A, Martinez JL, Tores C. Macrolide Resistance Genes in Enterococcus Spp. *Antimicrob Agents and Chemother* 2000; 44(4):967-71.
13. Woodford N. Glycopeptide-resistant enterococci: a decade of experience. *J Med Microbiol* 1998; 47(10):849-62.
14. Fraser SL. Enterococcal Infections. (Online). Available from: URL: <http://medscape.com/article/216993-overview>.
15. Theilacker C, Kruger WA, Kropec A, Huebner J. Rationale for the development of

- immunotherapy regimens against enterococcal infections. *Vaccine* 2004; 22(1):31-8.
16. Wang Y, Huebner J, Tzianabos AO, Martirosian G, Kasper DL, Pier GB. Structure of an antigenic teichoic acid shared by clinical isolates of *Enterococcus faecalis* and vancomycin-resistant *Enterococcus faecium*. *Carbohydr Res* 1999; 316(1-4):155-60.
 17. Koch S, Hufnagel M, Theilacker C, Huebner J. Enterococcal infections: Host response, therapeutic, and prophylactic possibilities. *Vaccine* 2004; 22(7):822-30.
 18. Macfaddin JF. Biochemical tests for identification of Medical Bacteria. Philadelphia: Lippincott Williams & Wilkins Press; 2000.
 19. Hekmat Y. Prevalence of urinary tract infection during out patient's follow-up renal transplantation admitted to reference laboratories of Iran: a 2-year period (2001-2003). Iranian congress of Microbiology, 2004 Oct 16-18, Tehran, Iran. [In Persian]
 20. Fatholazadeh B, B.Hashemi F, Emaneini M, Aligholi M, A.Nakhjavani F. Detection of Vancomycin Resistant Enterococci (VRE) Isolated from Urinary Tract (UTI) in Tehran, Iran. *DARU Journal* 2006; 14(3):141-5.
 21. Schouten MA, Hoogkamp-Korstanje JAA, Meis JFG, Voss A. The European VRE Study Group. Prevalence of Vancomycin-Resistant Enterococci in Europe. *Eur J Clin Microbiol Infect Dis* 2000; 19(11):816-22.
 22. Mohammadi F, Tabariae B, Sadeghifard N, Ghafoorian S, Maleki A. Evaluation of resistance frequency among *Enterococcus faecium* and *E. Faecalis* strains and detection of Van A/B genes in vancomycin resistance isolated by PCR Method in Ilam and Kermanshah Hospitals. *Ilam University of Medical Sciences Journal* 2011; 19(2):1-8. [In Persian]
 23. Noohi N, Talebi M, Ebrahimipour Gh, Pourshafie MR. The study of high level gentamicin resistance in *Enterococcus* isolated from healthy human in Tehran, 2007-8. *Iranian Journal of Medical Microbiology* 2009; 2(3-4):47-52. [In Persian]
 24. Guiney M, Urwin G. Frequency and Antimicrobial Susceptibility of Clinical Isolates of Enterococci. *Eur J Clin Microbiol Infect Dis* 1993; 12(5):362-6.
 25. Oskuri M, Farrokh P. Phenotypic and genotypic characterization of vancomycin-resistant Enterococci from clinical isolates. *Iranian Journal of Medical Microbiology* 2008; 2(1):15-22. [In Persian]
 26. Salah R, Dar-odeh N, Abu Hammad O, Shehabi AA. Prevalence of putative virulence factor and antimicrobial susceptibility OD *Enterococcus faecalis* isolates from patients with dental Disease. *BMC oral Health* 2008; 8(1):8-17.
 27. Harris AD, Nemoy L, Johnson JA, Martin-Carnahan A, L.Smith D, Standiford H, et al. Co-Carriage Rates of Vancomycin-Resistant *Enterococcus* and Extended-Spectrum Beta-Lactamase-Producing Bacteria Among a Cohort of Intensive Care Unit Patients: Implications for an Active Surveillance Program. *Infect Control Hosp Epidemiol* 2004; 25(2):105-8.
 28. Ghasemi A, Moniri R Khorshidi A, Gholam Musavi Gh. The survey of virulence factors of *Enterococcus faecalis* isolated from urine samples. *Iranian Journal of Medical Microbiology* 2009; 2(3):53-8. [In Persian]

بررسی فراوانی انتروکوک‌های مقاوم به ونکومايسين جدا شده از نمونه‌های بالینی بیمارستان شهید محمدی به روش E-test

زینب قلندرزاده دریایی^۱، صدیقه جوادیپور^۲، محمد کارگر^۳

^۱ دانشجوی کارشناسی ارشد، میکروبیولوژی، مرکز تحقیقات بیماریهای عفونی و گرمسیری، ^۲ دانشیار، گروه میکروبیولوژی، مرکز تحقیقات پزشکی مولکولی، دانشگاه علوم پزشکی هرمزگان، بندرعباس، ^۳ دانشیار، گروه میکروبیولوژی، دانشگاه آزاد اسلامی، واحد جهرم، جهرم، ایران.

مجله پزشکی هرمزگان سال نوزدهم شماره چهارم ۹۴ صفحات ۲۱۱-۲۱۷.

چکیده

مقدمه: انتروکوک‌ها باکتری‌های کوکوئید گرم مثبت‌اند که به صورت فلور نرمال در دستگاه گوارش در انسان، بسیاری از پستانداران و پرندگان وجود دارند و علاوه بر آن در محیط پراکنده هستند. انتروکوک مقاوم به ونکومايسين (VRE) یک مشکل مهم و در حال افزایش در بیمارستانهای سراسر جهان است. هدف از این پژوهش، بررسی فراوانی سویه‌های انتروکوک و الگوی حساسیت دارویی در نمونه‌های بالینی می‌باشد.

روش کار: این پژوهش به صورت مقطعی - توصیفی بر روی ۵۴ نمونه‌ی انتروکوک در سال ۱۳۹۱ انجام شد. برای شناسایی گونه‌های مختلف انتروکوک از کیت تشخیصی Rapid STR System استفاده شد. حساسیت آنتی بیوتیکی با روش دیسک دیفیوژن کربی - بائر و مطابق با دستورالعمل CLSI انجام شد. تعیین MIC ونکومايسين به روش E-Test انجام گرفت.

نتایج: از ۵۴ جدایه انتروکوک ۳۸ سویه (۷۰/۴۰٪) به گونه فیکالیس، ۱۰ سویه (۱۸/۵۰٪) به گونه فیسیوم، ۳ سویه (۵/۵۵٪) به گونه هیرا، یک سویه (۱/۸۵٪) به گونه موندتی، یک سویه (۱/۸۵٪) به گونه دورانس و یک سویه (۱/۸۵٪) به گونه آویوم تعلق داشت. ۱۳ سویه نسبت به ونکومايسين $\text{MIC} > 32 \mu\text{g/ml}$ داشتند. بیشترین مقاومت را با ۷۰/۴۰٪ به جنتامایسین و سفالکسین و کمترین مقاومت را با ۳/۷۰٪ به لاینزولید داشتند. بیشترین سویه مقاوم از نمونه ادرار (۷/۹٪) و در بخش داخلی (۴/۶۱٪) بدست آمد.

نتیجه‌گیری: به دلیل فراوانی قابل توجه VRE جدا شده از منطقه مورد پژوهش ضرورت انجام اقدامات کنترلی وجود دارد.

نویسنده مسئول:

دکتر صدیقه جوادیپور

مرکز تحقیقات پزشکی مولکولی

دانشگاه علوم پزشکی هرمزگان

بندرعباس - ایران

تلفن: +۹۸۹۱۳۳۳۹۵۳۳۷

پست الکترونیکی:

sedighjivadipour@yahoo.com

کلیدواژه‌ها: انتروکوک مقاوم به ونکومايسين - آنتی بیوتیک - بیمارستان.

نوع مقاله: پژوهشی

دریافت مقاله: ۹۲/۴/۲۹ اصلاح نهایی: ۹۲/۸/۱۱ پذیرش مقاله: ۹۲/۸/۲۹

ارجاع: قلندرزاده دریایی زینب، جوادیپور صدیقه، کارگر محمد. بررسی فراوانی انتروکوک‌های مقاوم به ونکومايسين جدا شده از نمونه‌های بالینی بیمارستان شهید محمدی به روش E-test. مجله پزشکی هرمزگان ۱۹ (۴) ۲۱۷-۲۱۱.